BioAlliance Pharma: Epidemiological study on Oropharyngeal Candidiasis and results on miconazole MBT* compliance were presented at the 51st ASTRO Annual Meeting
* Reuters is not responsible for the content in this press release.
PARIS--(Business Wire)--
Regulatory News:
Results on epidemiologic study on OroPharyngeal Candidiasis (OPC) in oncology
were presented at the 51st ASTRO (American Society for Therapeutic Radiology and
Oncology) Meeting in Chicago (From November 1st to November 5th).
Pr David Azria (Anticancer Center Montpellier) has presented the data collected
in 35 public and private oncology centers.
This study of 2027 cancer patients revealed a 10% prevalence (total number of
cases of a disease in a given population at a specific time) of OPC. Patients
receiving a combination of chemotherapy and radiotherapy are more likely to
suffer from OPC (22%) than those receiving chemotherapy or radiotherapy alone.
Highest prevalence was seen in patients with head and neck cancer (30%). Local
treatments, such as miconazole MBTù, amphotericin B or nystatin mouthwashes are
usually prescribed, as per treatment guidelines. Treatment compliance is
strongly increased with drugs administered once daily (miconazole MBT) versus
treatments with multiple daily dosing (amphotericin B or nystatin mouthwashes).
* miconazole MBT: MucoadhesiveBuccal Tablet, Loramyc® in Europe
About OPC
Also known as thrush is an oral fungal infection most common in individuals with
weakened immune systems - particularly those with HIV/AIDS and those undergoing
cancer treatments. OPC is a disruptive condition that results in lesions and
inflammation in the mouth, and includes symptoms such as soreness, burning
and/or altered taste.
About ASTRO
Radiation oncologists, radiation oncology nurses, medical physicists, radiation
therapists, dosimetrists and biologists comprise ASTRO`s more than 10,000
members, making it the largest radiation oncology organization of its kind.
These medical professionals, found at hospitals and cancer treatment centers
around the globe, make up the radiation therapy treatment teams that are
critical in the fight against cancer. These teams, which often include a
nutritionist and a social worker, treat more than 1 million cancer patients each
year.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma
(Paris:BIO) is a company which develops and markets innovative products in
France, especially in the fields of opportunistic infections and chemotherapy
complications. In areas where medical needs are insufficiently met, our targeted
approaches help overcome drug resistance and improve patient health & quality of
life. BioAlliance Pharma`s ambition is to become a leading player in these
fields by coupling innovation to patient needs.
For more information, visit the BioAlliance Pharma web site at
http://www.bioalliancepharma.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning BioAlliance Pharma SA and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors, which
could cause the actual results, financial condition, performance or achievements
of BioAlliance Pharma SA to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. BioAlliance Pharma SA is providing this communication as of this
date and does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results,
financial condition, performance or achievements of BioAlliance Pharma SA to
differ from those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document
filed with the AMF on April 7, 2009, which is available on the AMF website
(http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website
(http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini MD, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters